Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat vs allopurinol in APRT deficiency: urinary 2,8-dihydroxyadenine
2013-000975-33Phase 4Completed
- Sponsor
- Landspitali
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of febuxostat and allopurinol in 2,8-dihydroxyadenine nephropathy (2 arms), sponsored by Landspitali. Primary endpoint: Urinary 2,8-dihydroxyadenine excretion. Started Oct 2013; status: completed.
02
Drugs
febuxostatallopurinol
03
Conditions
2,8-dihydroxyadenine nephropathy
Beyond the preview
Go deeper on 2013-000975-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000975-33.